An early-phase, dose-escalation study of a hypofractionated approach to concurrent chemoradiation using an an adaptive stereotactic ablative radiotherapy (SABR) boost showed promising results in ...
The launch of a groundbreaking clinical trial in oncology and the publication of guidance from the US FDA highlight increasing support for the use of adaptive clinical trials in the development of new ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results